Retinopathies associated with antiretinal antibodies

Research output: Contribution to journalArticle

Abstract

The pathogenetic involvement of antibodies or cellular immunity to retinal proteins in humans is not clear. In this brief review, we have presented evidence that selected retinopathies are associated with the development of antiretinal antibodies. The initiating factors that contribute to the generation of these autoantibodies may vary with the different clinicopathological settings. In CAR, antibodies are directed against tumor-induced antigens that also recognize proteins within the retina. In infection-associated retinopathies, antibodies directed against an infectious agent may cross-react with retinal proteins or the antibodies react with retinal antigens released during the infection. In the retinal degenerative diseases, antibodies have been identified that react to a variety of retinal antigens. In these diseases it is difficult to determine if the antiretinal antibodies initiated the disease process or if the retinal degeneration occurred first and an immune response was later triggered against selected released retinal antigens. Irrespective of the initiating event, the presence of antiretinal antibodies may contribute to the pathologic processes involved in selected retinopathies. Presently, the identification of antiretinal antibodies is neither specific nor sensitive for the diagnosis of retinopathies. Nevertheless, demonstration of these antibodies may be helpful as diagnostic and prognostic markers in patients with retinal diseases. Analysis of immune-mediated vision loss is in its infancy, and a careful analysis and characterization of antiretinal antibody specificies will help in our understanding of the mechanisms and the diagnosis of patients with this form of vision loss.

Original languageEnglish (US)
Pages (from-to)853-858
Number of pages6
JournalClinical and Diagnostic Laboratory Immunology
Volume8
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Antibodies
Antigens
Retinal Diseases
Retinal Degeneration
Proteins
Neoplasm Antigens
Pathologic Processes
Infection
Cellular Immunity
Autoantibodies
Retina
Tumors
Demonstrations

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Retinopathies associated with antiretinal antibodies. / Hooks, J. J.; Tso, Mark O M; Detrick, Barbara.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 8, No. 5, 2001, p. 853-858.

Research output: Contribution to journalArticle

@article{ba128bb7ae6b489080953f637b979f0e,
title = "Retinopathies associated with antiretinal antibodies",
abstract = "The pathogenetic involvement of antibodies or cellular immunity to retinal proteins in humans is not clear. In this brief review, we have presented evidence that selected retinopathies are associated with the development of antiretinal antibodies. The initiating factors that contribute to the generation of these autoantibodies may vary with the different clinicopathological settings. In CAR, antibodies are directed against tumor-induced antigens that also recognize proteins within the retina. In infection-associated retinopathies, antibodies directed against an infectious agent may cross-react with retinal proteins or the antibodies react with retinal antigens released during the infection. In the retinal degenerative diseases, antibodies have been identified that react to a variety of retinal antigens. In these diseases it is difficult to determine if the antiretinal antibodies initiated the disease process or if the retinal degeneration occurred first and an immune response was later triggered against selected released retinal antigens. Irrespective of the initiating event, the presence of antiretinal antibodies may contribute to the pathologic processes involved in selected retinopathies. Presently, the identification of antiretinal antibodies is neither specific nor sensitive for the diagnosis of retinopathies. Nevertheless, demonstration of these antibodies may be helpful as diagnostic and prognostic markers in patients with retinal diseases. Analysis of immune-mediated vision loss is in its infancy, and a careful analysis and characterization of antiretinal antibody specificies will help in our understanding of the mechanisms and the diagnosis of patients with this form of vision loss.",
author = "Hooks, {J. J.} and Tso, {Mark O M} and Barbara Detrick",
year = "2001",
doi = "10.1128/CDLI.8.5.853-858.2001",
language = "English (US)",
volume = "8",
pages = "853--858",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Retinopathies associated with antiretinal antibodies

AU - Hooks, J. J.

AU - Tso, Mark O M

AU - Detrick, Barbara

PY - 2001

Y1 - 2001

N2 - The pathogenetic involvement of antibodies or cellular immunity to retinal proteins in humans is not clear. In this brief review, we have presented evidence that selected retinopathies are associated with the development of antiretinal antibodies. The initiating factors that contribute to the generation of these autoantibodies may vary with the different clinicopathological settings. In CAR, antibodies are directed against tumor-induced antigens that also recognize proteins within the retina. In infection-associated retinopathies, antibodies directed against an infectious agent may cross-react with retinal proteins or the antibodies react with retinal antigens released during the infection. In the retinal degenerative diseases, antibodies have been identified that react to a variety of retinal antigens. In these diseases it is difficult to determine if the antiretinal antibodies initiated the disease process or if the retinal degeneration occurred first and an immune response was later triggered against selected released retinal antigens. Irrespective of the initiating event, the presence of antiretinal antibodies may contribute to the pathologic processes involved in selected retinopathies. Presently, the identification of antiretinal antibodies is neither specific nor sensitive for the diagnosis of retinopathies. Nevertheless, demonstration of these antibodies may be helpful as diagnostic and prognostic markers in patients with retinal diseases. Analysis of immune-mediated vision loss is in its infancy, and a careful analysis and characterization of antiretinal antibody specificies will help in our understanding of the mechanisms and the diagnosis of patients with this form of vision loss.

AB - The pathogenetic involvement of antibodies or cellular immunity to retinal proteins in humans is not clear. In this brief review, we have presented evidence that selected retinopathies are associated with the development of antiretinal antibodies. The initiating factors that contribute to the generation of these autoantibodies may vary with the different clinicopathological settings. In CAR, antibodies are directed against tumor-induced antigens that also recognize proteins within the retina. In infection-associated retinopathies, antibodies directed against an infectious agent may cross-react with retinal proteins or the antibodies react with retinal antigens released during the infection. In the retinal degenerative diseases, antibodies have been identified that react to a variety of retinal antigens. In these diseases it is difficult to determine if the antiretinal antibodies initiated the disease process or if the retinal degeneration occurred first and an immune response was later triggered against selected released retinal antigens. Irrespective of the initiating event, the presence of antiretinal antibodies may contribute to the pathologic processes involved in selected retinopathies. Presently, the identification of antiretinal antibodies is neither specific nor sensitive for the diagnosis of retinopathies. Nevertheless, demonstration of these antibodies may be helpful as diagnostic and prognostic markers in patients with retinal diseases. Analysis of immune-mediated vision loss is in its infancy, and a careful analysis and characterization of antiretinal antibody specificies will help in our understanding of the mechanisms and the diagnosis of patients with this form of vision loss.

UR - http://www.scopus.com/inward/record.url?scp=0034828168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034828168&partnerID=8YFLogxK

U2 - 10.1128/CDLI.8.5.853-858.2001

DO - 10.1128/CDLI.8.5.853-858.2001

M3 - Article

VL - 8

SP - 853

EP - 858

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 5

ER -